文献速递主动脉外科

复杂性急性B型主动脉夹层TEVAR术后主动脉重塑

Aortic Remodeling After Endovascular Repair of Complicated Acute Type B Aortic Dissection.
PubMed 文献 · Ann Thorac Surg · 2016-12-16

本研究回顾了51例接受TEVAR治疗的复杂性急性B型主动脉夹层患者,分析其临床结局及主动脉重塑参数。结果显示院内死亡率为3.9%,1年死亡率为5.8%,TEVAR能有效促进胸段假腔血栓形成并稳定其尺寸,但腹段假腔多保持通畅,需长期监测动脉瘤形成。

要点

  • TEVAR治疗复杂性aTBAD的院内死亡率为3.9%,1年死亡率为5.8%。
  • DeBakey 3a患者假腔完全血栓形成/闭塞率为73%,DeBakey 3b近端降主动脉为100%。
  • 肾下段假腔78%保持通畅,需警惕远期动脉瘤形成。

核心结论

  • TEVAR治疗复杂性aTBAD的30天和1年死亡率低,但再干预率高于开放手术。
  • TEVAR能有效促进胸段假腔血栓形成并稳定其尺寸。
  • 腹主动脉假腔多保持通畅,必须仔细监测以预防远期动脉瘤形成。

研究设计与样本

  • 回顾性分析2012年1月至2015年12月连续51例因复杂性aTBAD接受TEVAR的患者。
  • 分析术前和术后影像学,评估胸腹主动脉五个位置的真假腔尺寸及假腔血栓状态。

主要发现

  • 院内死亡率为3.9%,1年死亡率为5.8%,卒中和下肢轻瘫发生率分别为3.9%和5.8%。
  • DeBakey 3a患者假腔完全血栓形成和/或闭塞率为73%;DeBakey 3b患者近端降主动脉为100%,降主动脉中点为78%。
  • 肾下段假腔在78%的患者中保持通畅。
  • TEVAR稳定了近端降主动脉尺寸(术前43 ± 9 mm vs 术后39 ± 7 mm;p = 0.07),但其他下游主动脉节段均出现显著扩张。
  • TEVAR显著增加了真腔体积(术前99 ± 51 cm3 vs 术后185 ± 70 cm3;p < 0.01)和主动脉总体积(术前314 ± 97 cm3 vs 术后391 ± 120 cm3;p = 0.02),同时抑制了假腔体积扩张(术前215 ± 67 cm3 vs 术后204 ± 79 cm3;p = 0.91)。

临床怎么用

  • TEVAR可作为复杂性aTBAD的有效治疗选择,能稳定胸段假腔并促进血栓形成。
  • 术后需长期密切监测腹主动脉假腔,因其常保持通畅且有动脉瘤形成风险。
  • 应关注TEVAR后再干预率较高的情况。

局限性

  • 样本量较小(51例),为单中心回顾性研究。
  • 随访时间有限,仅报告了1年死亡率。
  • 未与其他治疗方式(如开放手术)进行直接比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Thoracic endovascular aortic repair (TEVAR) is the optimal therapy for complicated acute type B aortic dissection (aTBAD). This study examined clinical outcomes and aortic remodeling parameters after TEVAR for patients with complicated aTBAD. METHODS: From January 2012 to December 2015, 51 patients underwent TEVAR for complicated aTBAD. Preoperative and postoperative imaging studies were analyzed for sizes of the true lumen (TL) and false lumen (FL) and for the FL thrombosis status at five locations in the thoracic and abdominal aorta. RESULTS: In-hospital and 1-year mortality rates were 3.9% and 5.8%, respectively. The incidence of stroke and paraparesis were 3.9% and 5.8%, respectively. In DeBakey 3a patients, TEVAR resulted in complete FL thrombosis and/or obliteration in 73% of patients. In DeBakey 3b patients, TEVAR resulted in complete FL thrombosis and/or obliteration in 100% of patients in the proximal descending thoracic aorta and 78% in the midpoint of the descending thoracic aorta. The infrarenal FL remained patent in 78% of patients. TEVAR stabilized the size of the proximal descending thoracic aorta (pre-TEVAR 43 ± 9 mm vs post-TEVAR 39 ± 7 mm; p = 0.07). However, significant aortic expansion was observed in all other downstream aortic segments. TEVAR resulted in a significant expansion in the TL volume (pre-TEVAR 99 ± 51 cm3 vs post-TEVAR 185 ± 70 cm3; p < 0.01) and total aortic volume (pre-TEVAR 314 ± 97 cm3 vs post-TEVAR 391 ± 120 cm3; p = 0.02) while inhibiting expansion of FL volume (pre-TEVAR 215 ± 67 cm3 vs post-TEVAR 204 ± 79 cm3; p = 0.91). CONCLUSIONS: TEVAR for complicated aTBAD results in low 30-day and 1-year mortality rates, with higher reintervention rates than observed with open operations. TEVAR is effective in thrombosing and stabilizing the size of the thoracic FL. The abdominal aortic FL remains patent and must be carefully scrutinized for long-term aneurysm formation.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Leshnower BG, Duwayri YM, Chen EP, et al. Aortic Remodeling After Endovascular Repair of Complicated Acute Type B Aortic Dissection. Ann Thorac Surg. 2016. PMID: 27993378. doi:10.1016/j.athoracsur.2016.09.057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。